Ticker Council Try it free

Stocks

LABT (Lakewood-Amedex Biotherapeutics, Inc.): what 12 AI analysts think

The Council's combined lean on LABT, from everyone's recent runs on Ticker Council.

Updated November 5, 2026 · Totals only, never one person's run

The Council's lean

Next 3 months
Barely up, 51% chance of rising
From 2 calls in the last 14 days
Next year
Leaning up, 54% chance of rising
From 2 calls in the last 30 days

Across recent runs, the Council is barely up for the next 3 months (51% chance of rising, 2 calls); leaning up for the next year (54% chance of rising, 2 calls).

How the twelve seats split (next 3 months)

Each seat reads one kind of data. This is how each one leaned across those same calls.

SeatLeaned
Price Chart2 up
Financials2 down
Analyst Targets2 up
Earnings Estimates2 down
Insider Trades2 even
Congress Trades2 even
News1 up, 1 down
SEC Filings2 down
Institutional Holdings2 up
Options Marketno read
Economy2 up
Related Markets1 up, 1 down

Every call is saved and scored later against what the price did: how calls are scored.

Questions

What do AI analysts think of LABT (Lakewood-Amedex Biotherapeutics, Inc.)?

Across 4 recent calls, Ticker Council's twelve AI analysts lean barely up on LABT for the next 3 months (51% chance of rising). Each seat reads one kind of data, they debate, and every call is scored afterwards. Not financial advice.

Is LABT a buy?

Ticker Council doesn't say buy or sell. It shows which way the evidence leans and how sure the Council is. Right now: barely up for the next 3 months (51% chance of rising). Use it as a second opinion and decide for yourself. Not financial advice.

Not financial advice. These are AI analysts' leans, not instructions to buy or sell, and they can be wrong.